Use cases
Use cases
Knowledge Graphs
Build better knowledge graphs with millions of novel high quality cause-and-effect relationships and contextual data
MoA & Explainability
Novel evidence to explain diseases and hypothesise treatment approaches
Biomarker Selection
Identify novel pharmacodynamic biomarkers from > 40 million documents
Target Selection
Infer drug-target-disease cause-and-effect relationships to ID novel targets and validate existing hypotheses
Indication Expansion
Use data annotations to identify diseases directly connected to a target based on well-established literature evidence
Knowledge Reviews
Systematically retrieve all relevant information to support go/no-go decisions
Solutions
Solutions
Data scientists
The most novel knowledge graph of rich, unique data
Biologists
Novel targets and never-before-seen biological research evidence
Information Managers
The forefront of federated architecture and GenAI
Company
Resources
Resources
News
Insights and blog posts
Events
Upcoming conferences
Downloads
Datasheets and other resources
Webinars
Live events and recordings
Knowledge Graphs in Drug Discovery
Virtual conference series
Galactic Web login
Request demo
Galactic Web login
Request demo
News
Daniel Jamieson awarded The Princess Royal Silver Medal
Daniel Jamieson awarded The Princess Royal Silver Medal
August 16, 2024
•
5 min read
Share this post
Biorelate News
Latest News
Discover new insights and updates for data science in biopharma
View all
Respected pharma data science pioneer Dr Ben Sidders to spearhead Biorelate's next growth phase as Chief Scientific Officer
Dr Sidders brings two decades of deep data science experience, honed across multiple therapeutic areas at Pfizer and AstraZeneca. He will build on Biorelate's strong track record of leveraging advanced data science methods to extract critical knowledge from vast amounts of biomedical literature. These new data-derived insights are enabling drug developers to identify new targets with maximum market potential.
Mapping disease signaling: a case study of roflumilast's potential in non-cystic fibrosis bronchiectasis
Using Galactic AI™, Biorelate synthesised insights from various biomedical studies into a coherent mechanism that underpins roflumilast's influence on airway inflammation and its prospective clinical benefits for non-CF bronchiectasis patients, by exploring the links between roflumilast and bronchiectasis.
Daniel Jamieson awarded The Princess Royal Silver Medal
Biorelate Founder and CEO is one of four to be presented with one of the Royal Academy of Engineering’s most prestigious individual awards
View all